RHYTHM PHARMACEUTICALS PIONEERING A PATH FORWARD
Live / Applied — Statement of use — processing complete, to examiner (as of 11 Mar 2026)
What this means for you
Not registered yet, but its 25 Sept 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98195639
- Mark type
- Design + words
- Filed
- 25 Sept 2023
- Published for opposition
- 30 Jul 2024
- Attorney of record
- Peter G. Byrne
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals and medicines for the treatment of metabolic diseases and disorders, namely, obesity
- Class 042 — Scientific and technological services: Research and product development services in the fields of metabolic diseases and disorders, namely, obesity
Owner
- Rhythm Pharmaceuticals, Inc., Boston, MA, US
- Rhythm Pharmaceuticals, Inc., Boston, MA, US
Prior registrations
Prosecution history
- 11 Mar 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 07 Oct 2025 — USE AMENDMENT FILED
- 07 Oct 2025 — TEAS STATEMENT OF USE RECEIVED
- 20 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 19 Sept 2025 — SOU EXTENSION 2 GRANTED
- 19 Sept 2025 — SOU EXTENSION 2 FILED
- 19 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 19 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 19 Mar 2025 — SOU EXTENSION 1 GRANTED
- 18 Mar 2025 — SOU EXTENSION 1 FILED
- 18 Mar 2025 — SOU TEAS EXTENSION RECEIVED
- 24 Sept 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 30 Jul 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 30 Jul 2024 — PUBLISHED FOR OPPOSITION
- 10 Jul 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED